Ptc Therapeutics, Inc. (PTCT) · Aug 28, 2026 · Acquisition

PTC Therapeutics signs $111M ST-920 deal; bankruptcy approval still pending

$111M ST-920 acquisition — $111M upfront plus up to $100M in milestones

PTC formalizes its $111M acquisition of Sangamo’s ST-920 gene therapy, but the deal still needs bankruptcy-court approval before closing.

The filing formalizes a deal the market already knew was coming. PTC had already announced on August 12, 2026 that it was the winning bidder for ST-920 in Sangamo’s bankruptcy auction, so this agreement is confirmation rather than a fresh strategic surprise. 〔0〕

The economics are now defined: $111 million upfront, with $100 million contingent on FDA approvals. The milestone structure places $80 million on accelerated approval and $20 million on full approval, meaning most of the additional consideration depends on regulatory execution rather than being paid immediately. (Item 1.01)

The immediate read is neutral because the headline terms were already disclosed, while closing risk remains. The transaction still requires Bankruptcy Court authorization, antitrust clearance and other customary conditions; either party can terminate if it has not closed by October 15, 2026, subject to exceptions. (Item 1.01) 〔1〕

The next information point is procedural, not financial. A Bankruptcy Court hearing to approve the acquisition is scheduled for September 10, 2026, making court approval the key near-term catalyst. (Item 1.01) 〔2〕

What to watch next

Bankruptcy Court approval hearing, September 10, 2026

Original filing on SEC EDGAR

More Ptc Therapeutics, Inc. news

PTC Therapeutics signs $111M ST-920 deal; bankruptcy approval still pending | PTCT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.